One small sensor has been winning over the hearts of its 7 million-plus2 global users for over a decade.
Now, we mean that literally.
New show our ing (CGM) technology is not only helping users manage their diabetes, but is the first CGM linked with fewer hospital admissions for heart-related complications in its users1, too.
Libre technology has long provided real-time glucose data to help its users make informed decisions about their activities, diet and medications, ultimately helping them live their best, healthiest lives. But the new findings demonstrate their ability to fight two health battles with one CGM, lowering cardiovascular disease-related hospitalizations in people living with Type 1 %1 and a reduction in hospitalizations for those with Type 2 diabetes on insulin.3 It’s a game-changer.
Why it Matters
Diabetes impacts 589 million people worldwide.4 From managing blood glucose levels to managing potential complications, the condition can have a variety of significant long-term effects on the people living with it. Heart health is a key one.5
People with Type 1 and Type 2 diabetes are two to four times more likely to develop heart disease. While the heart health risks associated with Type 2 diabetes are well-known, there’s low awareness about heart complications in people living with Type 1 diabetes. And those who have had serious low blood sugar episodes are twice as likely to be hospitalized for heart-related issues.6
On top of the health risk, there are the mental, emotional and financial implications of hospitalization on those living with diabetes, as well as on their loved ones.
How it Works
Peace of mind. That’s the power of continuous glucose monitoring. Our FreeStyle Libre technology, with a small sensor placed on the back of the upper arm, tracks glucose levels day and night to provide constant insight into the foods we eat, the exercise and activity we engage in, and what our bodies need to be at their best.
Essentially, it’s a window into the health of people with diabetes that can offer critical information on their well-being, helping manage the health impacts diabetes can cause.
Managing the potential complications of diabetes starts with managing diabetes itself. That’s where Libre technology thrives.
The experts that help people manage the condition are excited, too.
"I regularly treat people with diabetes who have problems with their blood vessels, resulting in heart attacks, strokes and amputations” said Ramzi Ajjan, M.D., professor of Metabolic Medicine at Leeds University and Leeds Teaching Hospitals Trust. These blood vessel problems, known collectively as cardiovascular disease, remain the main causes of ill health in people with diabetes. I am very excited to see data that show significant reduction in cardiovascular disease-related hospital admissions. It’s great to see the clear, positive impact of FreeStyle Libre technology on cardiovascular outcomes, making diabetes management more effective and improving the health of our patients."
That’s the power of one tiny sensor that can impact two crucial health challenges. That’s why not only advancing diabetes care, but helping millions address their overall health, is at the heart of who we are.
References
1 Olofsson, K., Diabetologia (2025):
2 Data on file, è Diabetes Care. Data based on the number of patients assigned to each manufacturer.
3 Nathanson, D., Diabetologia (2024):
4 International Diabetes Federation – Facts & figures, accessed April 2025 from: https://idf.org/about-diabetes/diabetes-facts-figures/
5 Medicine Plus – Long-term complications of diabetes, accessed May 2025 from: Long-term complications of diabetes: MedlinePlus Medical Encyclopedia
6 Amiel, SA, The Lancet Diabetes & Endocrinology (2019): https://doi.org/10.1016/S2213-8587(18)30315-2
IMPORTANT SAFETY INFORMATION
FREESTYLE LIBRE 2 SYSTEM
For Important Safety Information, please visit
Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.
The website you have requested also may not be optimized for your specific screen size.
Share